Zurück
• Marqibo®: Phase 2 relapsed ALL to commence; Phase 3 registration trials planned in
first-line ALL and NHL
• Talvesta™: Program on hold pending toxicology studies
• Zensana™: New formulation under active investigation and scale-up
• Management to host a conference call today at 8:30 a.m. EDT, 5:30 a.m. PDT
ganze Meldung unter www.hanabiosciences.com/press-releases/070323.pdf
first-line ALL and NHL
• Talvesta™: Program on hold pending toxicology studies
• Zensana™: New formulation under active investigation and scale-up
• Management to host a conference call today at 8:30 a.m. EDT, 5:30 a.m. PDT
ganze Meldung unter www.hanabiosciences.com/press-releases/070323.pdf
